Land: Israel
Sprog: engelsk
Kilde: Ministry of Health
NICOTINE
GSK CONSUMER HEALTHCARE, ISRAEL LTD
N07BA01
LOZENGES
NICOTINE 2 MG
PER OS
Not required
GSK CONSUMER HEALTHCARE SCHWEIZ AG, SWITZERLAND
NICOTINE
NICOTINE
An aid to smoking cessation, relief of symptoms associated with nicotine withdrawal.In smokers currently unable or not ready to stop smoking abruptly the lozenges may also be used as part of a program to reduce smoking prior to stopping completely.
2013-12-31
_The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in _ _June 2017 _ 1. NAME OF THE MEDICINAL PRODUCT Nicotinell Lozenges 1 mg Nicotinell Lozenges 2 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each piece of Nicotinell Lozenges 1 mg contains: Active substance: 1 mg nicotine (corresponding to 3.072 mg nicotine bitartrate dihydrate). Each piece of Nicotinell Lozenges 2 mg contains: Active substance: 2 mg nicotine (corresponding to 6.144 mg nicotine bitartrate dihydrate). Excipient(s): aspartame (0.01 g), maltitol (0.9 g) and sodium (9.8 mg). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lozenges White, mint flavoured, round biconvex lozenge 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nicotinell Lozenges are indicated in adults. As an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. In smokers currently unable or not ready to stop smoking abruptly the gum may also be used as part of a program to reduce smoking prior to stopping completely. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION CHILDREN AND ADOLESCENTS (< 18 YEARS) Nicotinell lozenges should not be used by people under 18 years of age. There is no experience in treating adolescents under the age of 18 with Nicotinell lozenges. ADULTS AND ELDERLY POSOLOGY: Nicotinell Lozenges 1 mg is recommended in smokers with a low to moderate nicotine dependency. It is not recommended in the case of smokers with a strong or very strong nicotine dependency. Nicotinell Lozenges 2 mg is intended to be used by smokers with a strong or very strong nicotine dependency and those who have previously failed to stop smoking with the aid of nicotine replacement therapy. The optimal dosage form is selected according to the following table: If an adverse event occurs with the use of the high dose form (2 mg lozenge), use of the low dose form (1 mg lozenge) should be considered. The initial dosage should be individualised on the basis of the patients nicotine dependence. Læs hele dokumentet